NDANASALSPRAYPriority Review
Approved
May 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 43m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPVEE (nalmefene hydrochloride) is a nasal spray opioid antagonist approved in May 2023 for emergency treatment of opioid overdose. It reverses respiratory depression caused by opioid use through rapid mu-opioid receptor antagonism. This is a small-molecule medication delivered via intranasal route for acute clinical intervention.
Peak16.1 years to LOE
Early-stage peak product with no identified direct competitors, suggesting market-building and team expansion phase under Indivior's commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence
Started Oct 2019
533 enrolled
Alcohol Dependence
Career Relevance
Working on OPVEE offers exposure to a newly approved, high-impact product in the urgent-care/emergency medicine space with strong societal relevance and Indivior's established overdose reversal franchise expertise. The lack of direct competition and long patent protection create stable, growth-oriented career opportunities in commercial roles focused on market development and healthcare provider adoption.
Brand Manager
Worked on OPVEE at Indivior? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.